It has been proposed that humans and wildlife have suffered adverse effects on reproductive health as a result of environmental exposure to chemicals that interact with the endocrine system (1) (2) (3) (4) . Mindful that a hypothesis is an idea that has not been sufficiently tested (5) , many independent efforts have been undertaken to evaluate the scope and legitimacy of the problem. As one of these undertakings, the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) convened the present study group with the aims of discerning the degree to which synthetic chemicals are implicated in this issue and advising toxicologists and ecotoxicologists on appropriate testing methods and hazard identification strategies. After compiling a list of currently available test methods (6) , we turned our attention to the identification of practical tests for endocrine disruption. To do that, we assumed that a range of endocrine disruption hazards are posed to wildlife and humans by environmental chemicals. We recognize the importance to any future regulatory initiatives in this area of demonstrating dose-response relationships, establishing the relevance of experimental models to humans and wildlife, and assessing exposures. However, these tasks were considered to be beyond our initial purpose.
In support of attempts to develop an appropriate hazard identification strategy for endocrine-disrupting chemicals, several regulatory initiatives have been launched, the most specific being a mandate by Congress that the EPA should have a regulatory framework on endocrine disruption in place by 1998 (7) . Such a condensed time frame carries with it the potential for the premature endorsement of unvalidated assays and unrefined testing strategies. This Table 2 according to the criteria recommended by Hill (9) for distinguishing between epidemiological association and causation, as recommended by Kavlock et al. (8) Kavlock et al. (8) .
In contrast to the situation in humans, several etiological links between exposure to synthetic endocrine-disrupting chemicals and adverse effects on wildlife have been established, mainly in contaminated environments (1) (2) (3) (4) . Nonetheless, the data supporting some of the suspected environmental links are as fragile as those noted by Kavlock et al. (8) for human effects. An example of this is provided by the predominant role played by the natural hormones estrone and 17p-estradiol, as opposed to synthetic xenobiotics, in the partial feminization of fish exposed to effluent of some municipal sewage treatment plants in the United Kingdom (11) (12) (13) (14) (15) (16) .
Given that there is significant conservation among animal species in the mechanisms that control sexual reproduction and development, it is suggested that it will be possible to adopt, at least initially, a common strategy for the identification of wildlife and human endocrine disruptors. For example, (8) * DDT/DDE/PCBs-conflicting data regarding their etiological involvement * EPA database on pesticides-no alerts to estrogenic mammary gland carcinogenesis * 450 NTP studies; 10% of studies induce mammary gland cancer, but chemicals unlikely to be estrogenic * Concomitant decline in uterine and male breast cancer observed * No evidence that endocrine-disrupting chemicals are a risk factor * The generality of the effect and its etiology are far from certain * First priority: hypotheses generated from field observations must be tested * First priority: studies to define the biological effects most likely to occur must be conducted * Studies to determine if there has been an increase in cases of immune dysregulation should be conducted Abbreviations: PCBs, polychlorinated biphenyls; EPA, U.S. Environmental Protection Agency; NTP, National Toxicology Program. (31) . The present proliferation of in vitro assays will inevitably continue apace with revelations of the complexity of normal sexual reproduction (32) . Therefore, prior to the formal, regulatory adoption of any of these assays, it is vital that the differences between existing assays be elucidated and critically examined, robust versions of the preferred and validated assays be developed for routine use, and an agreed-upon framework in which these assays should be used be derived. Failure to meet these needs will lead to delays in effective implementation similar to those that accompanied the introduction of mutagenicity assays.
Among the in vitro assays so far described, with the obvious exception of the fish hepatocyte assay and the possible exception of the receptor-based yeast assays, none appear to be metabolically competent. The use of in vitro mutagenicity assays in the absence of liver enzymes, e.g., S9 mix, would lead to the nondetection of many mammalian mutagens and carcinogens, and a similar problem should be anticipated in this area. For example, Shelby et al. (33) reported that the in vivo xenoestrogen methoxychlor is unable to bind to isolated estrogen receptors or activate those receptors in a mammalian cell transactivation assay. This observation led to the independent study of the same sample of methoxychlor in a yeast human estrogen receptor transactivation assay, with the goal of confirming its inactivity and establishing the importance of auxiliary metabolism. In fact, it was found to give a potent direct-acting positive response in the yeast assay, presumably reflecting the ability of the yeast cells to demethylate the methoxy groups yielding the active estrogenic phenol derivative (34) . This example confirms that the issue of metabolism in vitro has the potential to confound the validation of mammalian cell in vitro assays.
In addition to the general problem of metabolism and, again, based on experience gained with mutagenicity assay develVolume 105, Number 2, February 1997 * Environmental Health Perspectivesopment, it will be helpful if investigators can rapidly agree which assays are unreliable or nonspecific, and then share that conclusion openly. As an example, the polyclonal nature of MCF-7 cells (17) and the insensitivity of some of the clones to estradiol (35) , coupled with the problem of the assay's low specificity, suggest that this assay will have limited value for general screening purposes, despite the fact that it can be performed adequately in some laboratories. There is a need for such a clear conclusion to be openly agreed upon in the scientific community because, in its absence, the assay will continue to be used to define potential endocrine disruptors. All new test systems should be scrutinized by the broader scientific community before they are accepted for general use.
It is proposed that the development of in vitro assays for potential endocrine disruptors should be led by the naming of significant toxicities that are consequent to disruption of the endocrine system of intact organisms, followed by attempts to model these effects in vitro. When appropriate, such assays should then be refined to produce robust test protocols suitable for general use. This is in contrast to the uncoordinated proliferation of superficially validated assays that act as a brake on progress and lead to the generation of potentially large amounts of uninterpretable data. The need for scientific caution in progressing this new area of toxicology is illustrated by the failure to confirm (35, 36) the recent report by Arnold et al. (37) of synergism of estrogenic activity observed in vitro between a range of environmental chemicals. In Vivo Assays It is general practice in toxicology to screen for a potential toxic activity in vitro and to then confirm the expression of that activity in vivo before attributing a given toxic property to the test agent. For this and several other reasons outlined in this article, in vivo assays will assume a dominant position in screening strategies and risk assessment processes for endocrine disruption. Further, the trend common to other branches of toxicology of combining a range of end points in a single test protocol probably will apply equally to in vivo assays for endocrine disruption. However, an inevitable corollary to the use of multipleend point assays is that one is forced to rank end points, often in the absence of guiding data, when qualitatively divergent responses are obtained among the several end points being monitored. This indicates the need for an established hierarchy of endpoint sensitivities for studying endocrine disruption in a given organism.
In addition, the decision to conduct an assay in vivo carries with it a range of decisions regarding the choice of test species and strain, route of administration, and duration of dosing. The rodent uterotrophic assay illustrates why these generic problems should be discussed before, rather than after, the regulatory protocols for in vivo assays are fixed. The uterotrophic assay is often referred to as the gold standard of estrogenic activity in vivo. However, the data upon which this reputation is based were derived using a variety of protocols. The key variables were the use of rats or mice; the use of immature, hypophysectomized, or ovariectomized animals; the use of subcutaneous, intraperitoneal injection or oral administration of the test agent; and a dosing duration of between 3 and 6 days. Furthermore, some investigators recommend concomitant assessment of associated markers of estrogenic activity, such as vaginal opening, vaginal cornification, uterine epithelial cell height, or stromal proliferation (38, 39) .
To decide which of these many variables are important to the overall sensitivity of an assay will require assessment of a range of appropriate positive and negative endocrine disruptors. Similarly, it will be important to study the sensitivity and specificity of proposed estrogen action markers before they can replace existing markers. For example, lactoferrin mRNA levels in the immature mouse uterus can be increased several hundredfold when exposed to an estrogen (40) , but before this can be developed into a replacement for the uterotrophic assay, it will be necessary to evaluate the specificity of this response, and to establish that the estrogen and growth factor response elements in the mouse uterus lactoferrin gene are representative of that in humans. The failure to broach such basic questions in genetic toxicity research has led to the development of a large number of competing in vivo techniques with no general agreement on which of them are complementary to other assays and which are redundant.
Multiple Mechanisms ofAction
Agreement on a testing strategy to detect significant mammalian and wildlife estrogens would be relatively easy to achieve, and several such proposals have already been made (38, 39, 41) . However, such a strategy would not be expected to predict endocrine toxicities associated with disturbances to normal steroid hormone synthesis or metabolism, thyroid gland function, or pituitary and hypothalamic feedback control mechanisms. Such effects will be difficult, if not impossible, to simulate in vitro, and this again indicates the need for a high level of reliance on acute or subacute whole organism assays. For example, although some of the in vivo effects of PCBs may be predicted by in vitro assay results, particularly those effects mediated by direct receptor interactions, this will not always be true. As an example, it is unlikely that any cell-based assay could anticipate, at least for the correct reason, the ability of certain PCBs to increase the weight of rat testes (42) . This is because the effect is dependent upon PCB-induced hypothyroidism preventing the cessation of Sertoli cell division on about day 16 postpartum, an effect that is probably independent of the weak uterotrophic activity seen for PCBs in the 'rat (43) . Likewise, the testicular effects reported for BBP (13) are unlikely to be associated mechanistically with its mitogenicity to MCF-7 cells, just as the endocrine toxicities of p,p '-DDE are most probably mediated by its antiandrogenic properties, rather than by its initially defined estrogenic properties (44) .
Differentiation ofToxicities and Effects
The present uncertainty regarding the in vivo toxicities to expect of a chemical that has shown activity in vitro could lead to the measurement of a wide range of parameters in follow-up in vivo studies. Such toxicological fishing exercises might sometimes be justified, but to be useful they will require the separate recognition of significant toxicities and transient adaptive effects. For Key among the priorities suggested above are the need to continue to support studies to better define the reality and nature of the hazards posed, and to further investigate the original question of exposure of wildlife and humans to estrogen and androgen receptor agonists/antagonists. When progress has been made in these areas, attention can be given to the development of assays for other mechanisms of endocrine disruption. This will involve the development of assays that measure enzyme or hormone levels and activities in vivo. Such techniques may be difficult to refine into robust regulatory tests. This sequential approach to the many issues posed will enable coordinated progress to be made in defined areas. As general confidence in a core set of assays grows, consideration should be given to integrating endpoints into a reduced number of assays.
Finally, one should always keep in mind that the regulation of synthetic chemicals for endocrine disrupting properties may not alleviate the observed increases in human breast and testicular cancer or the apparent decrease in human sperm counts and sperm quality reported for some countries. Therefore, while attending to one possible contributor to these problems-synthetic chemicals-we should remain alert to the possible importance of alternative contributory factors, such as diet and lifestyle.
